Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

著者: Jeffrey Cohen, Alasdair Coles, Douglas L. Arnold, Christian Confavreux, Edward Fox, Hans-Peter Hartung, Eva Havrdová, Krzysztof Selmaj, Howard L. Weiner, Elizabeth Fisher, Vesna Brinar, Gavin Giovannoni, M. Stojanovic, Bella Ertik, Stephen Lake, David Margolin, Michael Panzara, D. A. S. Compston - The Lancet 2012 被引用: 1,198